The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis

Journal of Immunology

Volumn 178, Issue 6, 2007, Pages 3379-3389

  Kovačić, Nataša ^a   Lukić, Ivan Krešimir ^a   Grčević, Danka ^a   Katavić, Vedran ^a   Croucher, Peter ^b   Marušić, Ana ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; FAS ANTIGEN; FAS LIGAND; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW; CELL ASSAY; CELL CULTURE; CELL DIFFERENTIATION; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; IN VITRO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 33947271862     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.6.3379     Document Type: Article

References (40)

1. Grcevic, D., V. Katavic, I. K. Lukic, N. Kovacic, J. A. Lorenzo, and A. Marusic. 2001. Cellular and molecular interactions between immune system and bone. Croat. Med. J. 42: 384-392.
2. Weinstein, R. S., and S. C. Manolagas. 2000. Apoptosis and osteoporosis. Am. J. Med. 108: 153-164.
3. Sartorius, U., I. Schmitz, and P. H. Krammer. 2001. Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochemistry 2: 20-29.
4. Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976.
5. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317.
6. Adachi, M., S. Suematsu, T. Kondo, J. Ogasawara, T. Tanaka, N. Yoshida, and S. Nagata. 1995. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 11: 294-300.
7. Karray, S., C. Kress, S. Cuvellier, C. Hue-Beauvais, D. Damotte, C. Babinet, and M. Levi-Strauss. 2004. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J. Immunol. 172: 2118-2125.
8. Katavic, V., I. K. Lukic, N. Kovacic, D. Grcevic, J. A. Lorenzo, and A. Marusic. 2003. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J. Immunol. 170: 1540-1547.
9. Katavic, V., D. Grcevic, I. K. Lukic, V. Vucenik, N. Kovacic, I. Kalajzic, and A. Marusic. 2003. Non-functional Fas ligand increases the formation of cartilage early in the endochondral bone induction by rhBMP-2. Life Sci. 74: 13-28.
10. Mori, S., M. Nose, M. Chiba, K. Narita, M. Kumagai, H. Kosaka, and T. Teshima. 1997. Enhancement of ectopic bone formation in mice with a deficit in Fas-mediated apoptosis. Pathol. Int. 47: 112-116.
11. Bu, R., C. W. Borysenko, Y. Li, L. Cao, A. Sabokbar, and H. C. Blair. 2003. Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 33: 760-770.
12. Hatakeyama, S., N. Tomichi, Y. Ohara-Nemoto, and M. Satoh. 2000. The immunohistochemical localization of Fas and Fas ligand in jaw bone and tooth germ of human fetuses. Calcif. Tissue Int. 66: 330-337.
13. Ozeki, N., M. Mogi, H. Nakamura, and A. Togari. 2002. Differential expression of the Fas-Fas ligand system on cytokine-induced apoptotic cell death in mouse osteoblastic cells. Arch. Oral Biol. 47: 511-517.
14. Wu, X., M. A. McKenna, X. Feng, T. R. Nagy, and J. M. McDonald. 2003. Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology 144: 5545-5555.
15. Park, H., Y. K. Jung, O. J. Park, Y. J. Lee, J. Y. Choi, and Y. Choi. 2005. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J. Immunol. 175: 7193-7201.
16. + T cells. Arthritis Rheum. 48: 3350-3358.
17. Kalajzic, I., Z. Kalajzic, M. Kaliterna, G. Gronowicz, S. H. Clark, A. C. Lichtler, and D. Rowe. 2002. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J. Bone Miner. Res. 17: 15-25.
18. Grcevic, D., S. K. Lee, A. Marusic, and J. A. Lorenzo. 2000. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J. Immunol. 165: 4231-4238.
19. Shipman, C. M., M. J. Rogers, J. F. Apperley, R. G. Russell, and P. I. Croucher. 1997. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol. 98: 665-672.
20. Godard, T., E. Deslandes, P. Lebailly, C. Vigreux, F. Sichel, J. M. Poul, and P. Gauduchon. 1999. Early detection of staurosporine-induced apoptosis by comet and annexin V assays. Histochem. Cell Biol. 112: 155-161.
21. Siegel, R. M., F. K. Chan, H. J. Chun, and M. J. Lenardo. 2000. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1: 469-474.
22. Schroeder, T. M., E. D. Jensen, and J. J. Westendorf. 2005. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res. C. Embryo Today 75: 213-225.
23. Komori, T., H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R. T. Bronson, Y. H. Gao, M. Inada, et al. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
24. Aubin, J. E. 1998. Advances in the osteoblast lineage. Biochem. Cell Biol. 76: 899-910.
25. Malaval, L., F. Liu, P. Roche, and J. E. Aubin. 1999. Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro. J. Cell. Biochem. 74: 616-627.
26. Ducy, P., and G. Karsenty. 1995. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol. Cell. Biol. 15: 1858-1869.
27. Lacey, D. L., E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
28. De Maria, R., U. Testa, L. Luchetti, A. Zeuner, G. Stassi, E. Pelosi, R. Riccioni, N. Felli, P. Samoggia, and C. Peschle. 1999. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 93: 796-803.
29. Alenzi, F. Q., S. B. Marley, J. L. Lewis, A. Chandrashekran, A. N. Warrens, J. M. Goldman, and M. Y. Gordon. 2002. A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics. Exp. Hematol. 30: 1428-1435.
30. Kalajzic, I., A. Staal, W. P. Yang, Y. Wu, S. E. Johnson, J. H. Feyen, W. Krueger, P. Maye, F. Yu, Y. Zhao, et al. 2005. Expression profile of osteoblast lineage at defined stages of differentiation. J. Biol. Chem. 280: 24618-24626.
31. Imamura, R., K. Konaka, N. Matsumoto, M. Hasegawa, M. Fukui, N. Mukaida, T. Kinoshita, and T. Suda. 2004. Fas ligand induces cell-autonomous NF-κB activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-α. J. Biol. Chem. 279: 46415-46423.
32. Kang, T. B., T. Ben-Moshe, E. E. Varfolomeev, Y. Pewzner-Jung, N. Yogev, A. Jurewicz, A. Waisman, O. Brenner, R. Halfner, E. Gustafsson, et al. 2004. Caspase-8 serves both apoptotic and nonapoptotic roles. J. Immunol. 173: 2976-2984.
33. Mariani, S. M., B. Matiba, E. A. Armandola, and P. H. Krammer. 1994. The APO-1/Fas (CD95) receptor is expressed in homozygous MRI/lpr mice. Eur. J. Immunol. 24: 3119-3123.
34. Bossen, C., K. Ingold, A. Tardivel, J. L. Bodmer, O. Gaide, S. Hertig, C. Ambrose, J. Tschopp, and P. Schneider. 2006. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 281: 13964-13971.
35. Balkow, S., A. Kersten, T. T. Tran, T. Stehle, P. Grosse, C. Museteanu, O. Utermohlen, H. Pircher, F. von Weizsacker, R. Wallich, et al. 2001. Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J. Virol. 75: 8781-8791.
36. Wu, X., G. Pan, M. A. McKenna, M. Zayzafoon, W. C. Xiong, and J. M. McDonald. 2005. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J. Bone Miner. Res. 20: 107-116.
37. Lee, S. K., A. E. Gardner, J. F. Kalinowski, S. L. Jastrzebski, and J. A. Lorenzo. 2006. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38: 678-685.
38. Yin, T., and L. Li. 2006. The stem cell niches in bone. J. Clin. Invest. 116: 1195-1201.
39. de Vries, E. G., T. Timmer, N. H. Mulder, C. M. van Geelen, W. T. van der Graaf, D. C. Spierings, M. N. de Hooge, J. A. Gietema, and S. de Jong. 2003. Modulation of death receptor pathways in oncology. Drugs. Today 39(Suppl. C): 95-109.
40. Askenasy, N., E. S. Yolcu, I. Yaniv, and H. Shirwan. 2005. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105: 1396-1404.